Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “L-dopa Induced Dyskinesia”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Study completedNCT00888004
What this trial is testing

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

Who this might be right for
Parkinson's DiseaseL-dopa Induced Dyskinesia
Novartis 28
Testing effectiveness (Phase 2)Study completedNCT01538329
What this trial is testing

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

Who this might be right for
Parkinson Disease
University Hospital, Toulouse 210
Testing effectiveness (Phase 2)Study completedNCT01173731
What this trial is testing

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Who this might be right for
Parkinson DiseaseDyskinesia, Drug-InducedLevodopa
Novartis Pharmaceuticals 66
Not applicableStudy completedNCT02200887
What this trial is testing

Sleep Homeostasis in Parkinson's Disease

Who this might be right for
Parkinson Disease
Salvatore Galati 48
Testing effectiveness (Phase 2)Study completedNCT01092065
What this trial is testing

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

Who this might be right for
Parkinson's Disease
Novartis 23
Testing effectiveness (Phase 2)Study completedNCT00076674
What this trial is testing

Levetiracetam Treatment of L-dopa Induced Dyskinesias

Who this might be right for
DyskinesiasParkinson Disease
National Institute of Neurological Disorders and Stroke (NINDS) 40
Testing effectiveness (Phase 2)Study completedNCT00314288
What this trial is testing

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Who this might be right for
Parkinson's DiseaseDyskinesia
EMD Serono 360
Testing effectiveness (Phase 2)Study completedNCT01385592
What this trial is testing

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Who this might be right for
DyskinesiasParkinson DiseaseMovement Disorders+1 more
Novartis Pharmaceuticals 78
Testing effectiveness (Phase 2)Study completedNCT00582673
What this trial is testing

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

Who this might be right for
Parkinson's Disease
Novartis 31
Not applicableActive Not RecruitingNCT02347254
What this trial is testing

ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease

Who this might be right for
Parkinson's Disease
InSightec 6
Testing effectiveness (Phase 2)Study completedNCT00986414
What this trial is testing

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Who this might be right for
Parkinson DiseaseDyskinesias
Novartis 260
Testing effectiveness (Phase 2)Study completedNCT03531060
What this trial is testing

A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

Who this might be right for
Parkinson Disease
Integrative Research Laboratories AB 15
Testing effectiveness (Phase 2)Study completedNCT01491529
What this trial is testing

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Who this might be right for
DyskinesiasParkinson DiseaseMovement Disorders+2 more
Novartis Pharmaceuticals 154
Not applicableUnknownNCT02578849
What this trial is testing

Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia

Who this might be right for
Parkinson´s Disease
Aarhus University Hospital 45
Testing effectiveness (Phase 2)Study completedNCT01113320
What this trial is testing

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

Who this might be right for
Parkinson's Disease
Newron Pharmaceuticals SPA 26
Not applicableUnknownNCT04173832
What this trial is testing

Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

Who this might be right for
L-DOPA-Induced Dyskinesia
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 100
Testing effectiveness (Phase 2)UnknownNCT04147949
What this trial is testing

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Who this might be right for
Parkinson DiseaseDyskinesia, Medication-InducedL-Dopa Causing Adverse Effects in Therapeutic Use
VistaGen Therapeutics, Inc. 20
Testing effectiveness (Phase 2)Study completedNCT05148884
What this trial is testing

Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia

Who this might be right for
Medication-Induced Dyskinesia
Neurolixis SAS 27
Testing effectiveness (Phase 2)Study completedNCT01474421
What this trial is testing

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Who this might be right for
DyskinesiasDrug-induced
Novartis Pharmaceuticals 71
Testing effectiveness (Phase 2)Study completedNCT01491932
What this trial is testing

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Who this might be right for
DyskinesiasParkinson DiseaseMovement Disorders+2 more
Novartis Pharmaceuticals 129